Results 11 to 20 of about 174,072,709 (188)

Soluble Suppression of Tumorigenicity‐2 Predicts Mortality and Right Heart Failure in Patients With a Left Ventricular Assist Device [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Soluble suppression of tumorigenicity‐2 (sST2) predicts mortality in patients with heart failure. The predictive value of sST2 in patients with a left ventricular assist device remains unknown.
Lieke Numan, Emmeke Aarts, Faiz Ramjankhan, Marish I. F. Oerlemans, Manon G. van der Meer, Nicolaas de Jonge, Anne‐Marie Oppelaar, Hans Kemperman, Folkert W. Asselbergs, Linda W. Van Laake   +9 more
doaj   +5 more sources

Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement. [PDF]

Clin Exp Med, 2023
AbstractInterleukin (IL)-33 is part of the IL-1 family of cytokines and soluble suppression of tumorigenicity 2 (sST2) is part of the family of IL-1 receptors. In systemic sclerosis (SSc), IL-33 and sST2 are involved in cardiac manifestations such as diastolic dysfunction (DD), autonomic dysfunction (AD) and right ventricular–pulmonary arterial ...
Iannazzo F, Pellicano C, Colalillo A, Ramaccini C, Romaniello A, Gigante A, Rosato E.   +6 more
europepmc   +6 more sources

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis [PDF]

International Journal of Cardiology: Heart & Vasculature, 2021
Objectives: Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family. It is raised in various cardiovascular diseases, but its value in predicting disease severity or mortality outcomes has been controversial ...
Christina Ip, King Sum Luk, Vincent Lok Cheung Yuen, Lorraine Chiang, Ching Ki Chan, Kevin Ho, Mengqi Gong, Teddy Tai Loy Lee, Keith Sai Kit Leung, Leonardo Roever, George Bazoukis, Konstantinos Lampropoulos, Ka Hou Christien Li, Gary Tse, Tong Liu   +14 more
doaj   +4 more sources

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure

Chinese Medical Journal, 2016
Background: Many studies have explored the diagnostic performance of soluble suppression of tumorigenicity-2 (sST2) for heart failure (HF), but the results are inconsistent.
Dong-Hui Huang, Hao Sun, Jing-Pu Shi
doaj   +4 more sources

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis. [PDF]

Ann Lab Med, 2016
Soluble suppression of tumorigenicity 2 (sST2) has emerged as a biomarker of cardiac stretch or remodeling, and has demonstrated a role in acutely decompensated heart failure. However, its role in sepsis-induced cardiac dysfunction is still unknown.
Yang HS, Hur M, Kim H, Magrini L, Marino R, Di Somma S, GREAT Network.   +6 more
europepmc   +5 more sources

Circulating soluble suppression of tumorigenicity-2 and the recurrence of atrial fibrillation after catheter ablation: A meta-analysis [PDF]

Biomolecules & Biomedicine
Soluble suppression of tumorigenicity-2 (sST-2), a marker of myocardial fibrosis and remodeling, has been related to the development of atrial fibrillation (AF). The aim of this meta-analysis was to evaluate the relationship between baseline serum sST-2
Yanyu Shi, Zepeng Zhang, Tianyang Zhang, Linlin Zhang, Shan An, Ying Chen   +5 more
doaj   +4 more sources

Soluble suppression of tumorigenicity-2 changes during cardiotoxic cancer treatment: a systematic review and meta-analysis [PDF]

Frontiers in Cardiovascular Medicine
BackgroundSoluble suppression of tumorigenicity-2 (sST2) is a promising biomarker of cardiovascular disease and heart failure. Data about the changes in sST2 concentrations during cancer treatment and the relationship with cancer treatment-related ...
Luca Fazzini, Simone Angius, Nicola Campana, Luca Pascalis, Martino Deidda, Giordano Maria Pugliesi, Giordano Maria Pugliesi, Vincenzo Quagliariello, Nicola Maurea, Carlo Gabriele Tocchetti, Carlo Gabriele Tocchetti, Carlo Gabriele Tocchetti, Carlo Gabriele Tocchetti, Pietro Ameri, Pietro Ameri, Christian Cadeddu Dessalvi   +15 more
doaj   +4 more sources

Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study [PDF]

Renal Failure, 2020
Background Both soluble suppression of tumorigenicity 2 (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are promising biomarkers associated with the adverse clinical outcomes of dialysis patients.
Zhiyu Wang, Zijin Chen, Haijin Yu, Xiaobo Ma, Chunli Zhang, Bin Qu, Wen Zhang, Xiaonong Chen   +7 more
doaj   +3 more sources

Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study [PDF]

Journal of Clinical Medicine, 2023
Right heart failure is a major challenge in clinical practice. Soluble Suppression of Tumorigenicity-2 (sST2), a member of the interleukin-1-receptor family, may have clinical prognostic value. The aim of this study was to analyze whether sST2 correlates
Anja Haase-Fielitz, Michael Lichtenauer, Marwin Bannehr   +2 more
exaly   +3 more sources

Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia. [PDF]

J Matern Fetal Neonatal Med, 2023
La prééclampsie et les troubles de la croissance fœtale sont des affections spécifiques à la grossesse qui partagent des mécanismes physiopathologiques communs. Pourtant, on ne sait pas pourquoi certains patients développent une prééclampsie alors que d'autres éprouvent une restriction de la croissance fœtale, ou une combinaison des deux présentations ...
Kanninen T, Jung E, Gallo DM, Diaz-Primera R, Romero R, Gotsch F, Suksai M, Bosco M, Chaiworapongsa T.   +8 more
europepmc   +3 more sources